

Nanotoxicity of Inert Materials: The Case of Gold, Silver and Iron

Muhammad Umair¹, Ibrahim Javed², Mubashar Rehman³, Asadullah Madni³, Aqeel Javeed¹, Aamir Ghafoor⁴, Muhammad Ashraf¹

¹ Department of Pharmacology and Toxicology, University of Veterinary and Animal Sciences (UVAS) Lahore, Pakistan. ² Department of Chemistry, SBA School of Science & Engineering (SBASSE), Lahore University of Management Sciences (LUMS), DHA, Lahore Cantt - 54792, Lahore, Pakistan. ³ Department of Pharmacy, Islamia University of Bahawalpur, Bahawalpur, 63100 Pakistan. ⁴ University Diagnostic Laboratory, University of Veterinary and Animal Sciences (UVAS) Lahore, Pakistan.

Received, April 6, 2016; Revised, May 16, 2016; Accepted, May 16, 2016, Published, May 16, 2016

ABSTRACT - Nanotechnology has opened a new horizon of research in various fields including applied physics, chemistry, electronics, optics, robotics, biotechnology and medicine. In the biomedical field, nanomaterials have shown remarkable potential as theranostic agents. Materials which are considered inert are often used in nanomedicine owing to their nontoxic profile. At nanoscale, these inert materials have shown unique properties that differ from bulk and dissolved counterparts. In the case of metals, this unique behavior not only imparts paramount advantages but also confers toxicity due to their unwanted interaction with different cellular processes. In the literature, the toxicity of nanoparticles made from inert materials has been investigated and many of these have revealed toxic potential under specific conditions. The surge to understand underlying mechanism of toxicity has increased and different means have been employed to overcome toxicity problems associated with these agents. In this review, we have focused nanoparticles of three inert metallic materials *i.e.* gold, silver and iron as these are regarded as biologically inert in the bulk and dissolved form. These materials have gained wider research interest and studies indicating the toxicity of these materials are also emerging. Oxidative stress, physical binding and interference with intracellular signaling are the major role player in nanotoxicity and their predominance is highly dependent upon size, surface coating and administered dose of nanoparticles. Current strategies to overcome toxicity have also been reviewed in the light of recent literature. The authors also suggested that uniform testing standards and well-designed studies are needed to evaluate nanotoxicity of these materials that are otherwise considered as inert.

This article is open to **POST-PUBLICATION REVIEW**. Registered readers (see "For Readers") may **comment** by clicking on ABSTRACT on the issue's contents page.

INTRODUCTION

Nanotechnology has emerged as one of the exciting and novel field of science in last few decades. The history of nanoparticles traces back to ninth century when metallic nanoparticles, not realized at that time, were used as paint to decorate ports and windows, making them distinguishable among other subjects (1, 2). Nanoparticles are the particles with size less than 100 nm in any single dimension (3). This definition is based on the fact that particles in this size range possess unique structural properties that differ significantly from their bulk and dissolved counterparts. However, this definition may not serve well for nanoparticles in biomedical applications where pharmacological and chemical aspects are of pivotal consideration along with size and structure. Nanoparticles that show improved characteristics

with size below 100 nm are used majorly in diagnostic, like quantum dots, metal nanoclusters and paramagnetic particles while those for therapeutic applications has size usually above 100 nm like micelles, dendrimers, liposomes and polymersomes all loaded with drug (4, 5). Nanoparticles for drug delivery are designed to carry payload in desired temporal and spatial specifications.

Corresponding Authors: Mubashar Rehman; Address: Department of Pharmacy, Khawaja Fareed Campus, The Islamia University of Bahawalpur, Railway Road, Bahawalpur, Pakistan. Email: Ph.mubashar@hotmail.com; Asadullah Madni; Address: Department of Pharmacy, Khawaja Fareed Campus, The Islamia University of Bahawalpur, Railway Road, Bahawalpur, Pakistan. Email: Asadullah.madni@iub.edu.pk

They may be considered acceptable with size up to 300 nm which is sufficiently small to avoid reticuloendothelial (RES) systems and blocking of blood vessels when administered intravenously (6). They present immensely large surface area and surface modification opportunities which has made them an attractive tool to deliver bioactive molecules specifically to target pharmacological sites in body (7, 8). In some cases, specific characteristics may be imparted to drug delivery nanoparticles e.g. lipophilic surface modifications can make them cross blood brain barrier-suitable for CNS drug delivery (9, 10). Nanoparticle, after intravenous administration, are rapidly taken up by reticuloendothelial (RES) system which lead to their elimination from the body. This problem can be overcome by incorporating stealth property to nanoparticles (11). Polyethylene glycol (PEG is most widely used polymer for stealth coating which attracts water on nanoparticles surface to prevent opsonization and escape immune system (Figure 1).

Achieving different pharmacological and pharmaceutical milestones are possible by nanoparticles engineering and encapsulating drug inside it, without any chemical modifications in structure of drug molecule which may compromises its optimum pharmacological and toxicological balance. Nanoparticles have been modified in different ways to ensure site specific drug release, sparing the rest of the body cells from unwanted exposure. The slightly acidic pH (~6) of tumor microenvironment from rest of physiological pH (7.4) is targeted by making acid cleavable ligation of drug on surface of nanoparticles. Another strategy is to exploit overexpressing receptors on cancer cells like folic acid, hyaluronic acid and transferrin. These molecules if conjugated on surface of nanoparticles, will drive it directly to the cancer cells (12). Immune system recognize and produces antibodies against infectious organisms and tumor cells. Attempts have been made to decorate these antibodies on surface of nanoparticles for tumor targeting and utilizing their specificity in this regard. Monoclonal antibodies, a purified form of antibodies against single cancer epitope, can be covalently bound to nanoparticles that will circulate throughout the circulation and target only cancer cells (13, 14). Cancer tissues are rapidly proliferating and need large supply of blood to bring nutrients and carry away wastes. For this reason, cancer cells have leaky vasculature to allow permit free movement of substance in and out of cancer. This provides a passive targeting mechanism

to nanoparticles as they are can cross leaky vasculature of cancer tissues more easily, a process known as enhanced permeation and retention (EPR) effect (15). The newly formed blood vessels also offer resistance to the blood flow in this area hence increasing the retention of nanoparticles in the tumor mass (16).

More recently, research interest has shifted to devise theranostics nanoparticles making them immensely attractive in diagnosis and treatment (10). Gold, silver and iron are three widely used materials that are considered inert to biological systems because they are biocompatible and lack toxicity. These nanoparticles are also supposed to have biological activity like silver nanoparticles (AgNPs) have very well (9) documented antibacterial activity (17), gold nanoparticles (AuNPs) have cytotoxic, oral bioavailability enhancing and immunomodulatory effects, which may be an added advantage of these particles in treatment of diseases like multi drug resistant (MDR) infections and tumors (4, 18). Iron nanoparticles (IONPs) are being explored for contrast agents in magnetic resonance imaging (MRI) for tumor localization and pharmacokinetics of nanoparticles (19). Diagnostic applications of gold, silver and iron based nanoparticles are due to their ability to respond to a wide variety of external stimuli such as infra-red radiation, magnetic field and ultrasonic waves (20-22). These nanoparticles also offer opportunity of "clickable" release of encapsulated drugs when they reach target site (11). In addition, nanoparticles of gold, iron and silver are increasingly used for dual function nanoparticles that can help in diagnosis and treatments of different disease after single administration of such nanoparticles. One example is image guided therapy in which nanoparticles can locate and kill malignant cancer cells with loaded drug or burn it by heat produced after alternating photothermal exposure (23, 24). On the other hand, metallic nanoparticles also possess some detrimental effects like genotoxicity, inflammation, oxidative stress and interference with intracellular signaling (25-27). Such toxicity problems are encountered with these relatively inert materials when they are used at nanoscale. Toxicity of nanomaterials is usually described to be dose dependent which is further associated with size and surface engineering (28).

We summarized in this review, the aspects which are important from the perspective of drug delivery and toxicity of three commonly used

metallic nanoparticles i.e. gold, silver and iron. This review covers recent literature to elucidate underlying mechanisms of toxicity, so far established, in different conditions that are encountered *in vivo*. Attempts were also made to highlight currently formulated strategies to reduce toxicity of these nanomaterials and future prospects in the light of some studies already performed in this regard.

GOLD NANOPARTICLES

Gold is one of the most widely used material which is directly in contact with human body. Aurotherapy or Chrysotherapy is use of gold in medicine and use of raw gold for medicinal purpose can be traced back as far as the Chinese in 2500 B.C. In Medieval ages, Au was considered as heavenly precious glittering substance; which upon using against diseases can produce some relief. The methodological research about pharmacology of gold started in 1890, when Koch found its bactericidal activity against *tuberculosis bacilli*. The research about gold medicine gains its peak upon unrevealing of favorable results in arthritis leading to the

development of anti-rheumatic agents like auranofin and disodium aurothiomalate (30). The toxicological symptoms in patients and unclear mode of action of gold in arthritis/inflammation imparted some gaps in pharmacology of aurhotherapy. AuNPs of different sizes with engineered biocompatible surface is currently acting as a bridge to reveal the pharmacodynamics and kinetics of gold in therapeutics (31). Current exploration on unveiling the biological applications of AuNPs include capping with biofunctional moieties like peptides and carbohydrates and looking for cellular insult or control of cellular processes (32, 33). Similarly drug delivery and photothermal therapy of cancer is another direction being debated for biomedical applications of AuNPs. Moreover, gold nanoparticles can enhance therapeutic efficacy of co-administered drugs (18). The surface plasmon resonance (SPR) and light reflecting ability of AuNPs have made them a good tool as a diagnostic agent (9). Surface functionalization and ability of AuNPs to bind with thiols and amine groups have been used for making nanoparticles as a vector for drug and DNA (34, 35).




Figure 1: Schematic representation of influence by varying the density of PEG coating on nanoparticles: interaction with blood components and subsequent uptake by macrophages. The upper panel shows density of PEG on nanoparticles surface. Middle panel shows how type and amount of blood proteins interaction with nanoparticles varies with PEG density. Similarly, lower panel shows that serum dependent uptake by macrophage decreases as PEG density increases whereas serum independent uptake increases; (taken from (29) with permission)

The enhanced permeability and retention of small sized nanoparticles have given them an added advantage for use against diseases like cancer where the permeation of tumor vasculature has been exploited to selectively deliver the nanoparticles to tumor site (36). Enhanced permeability and retention, surface functionalization, SPR and photo thermal tumor ablation approach have been collectively exploited in search of theranostic applications of gold based nanomaterials (37). Despite of dramatic utilities of AuNPs there are some toxicological threats associated with their use as theranostics. AuNPs are considered as the safest metallic nanoparticles however toxicity is always subjected to considerable debate (38, 39) and in some studies toxicity is also documented (4, 5, 18, 40). The reported damages are particularly important due to their genetic, hepatic and renal toxicity nature even at lower doses (41). Toxicity of AuNPs is also reported on reproductive cells which may lead to anomalies in offspring (42). The critical analysis of the conditions reporting toxicity of AuNPs indicates that they shows sign of toxicity only specific conditions. If we could control those underlying parameters, the plethora of advantages of AuNPs may be availed without much of their side effects. The tools to control the side effect of these particles are discussed in the following sections.

Size and Shape

The size of AuNPs exerts dramatic effects on the interaction of these particles with macromolecules of living system. In 2007 Pan et al. performed experiments to evaluate toxicity of AuNPs in the range of 0.5 nm to 15 nm. They found that particles in the range of 1 - 2 nm are more cytotoxic than particles either smaller or larger than those. The results were very interesting in the sense that one cannot draw conclusion as to the safe size range. They also found that AuNPs of 1.2 nm lead to apoptosis whereas AuNPs of 1.4 nm produced necrosis (43). The cytotoxicity and associated necrosis is further confirmed by cytotoxicity against cell line of melanoma, macrophages, and fibroblasts. A logical explanation of this abnormal behavior is the fitting of the nanoparticles in the pockets of DNA coil or 3D quaternary structure of proteins (44). This pocket-fitting model is also supported by DNA or protein mediated synthesis of Au nanoclusters (NCs) where reduced Au atoms are grouped inside disulfide pockets in proteins or in folding of DNA duplex (45-49). Later in 2009, Pan et al. explained that toxicity

of AuNPs as small as 1.4 nm is due to oxidative stress and damage to mitochondrial integrity (50). In another work done by (51) the same sized (1.4 nm) AuNPs have shown the ability to catalyze the reaction in conversion of ring shaped protein "trp RNA-binding Attenuation Protein" to capsid shaped protein. These result suggest that particles in the size range of 1-2 nm have intrinsic ability to bind with biological macromolecules leading to protein configuration conversion. This intrinsic activity may be an unwanted pharmacological effect where inert AuNPs are desirable. Similarly, teratogenic effects of AuNPs can be attributed to size dependent passage of nanoparticles from maternal blood to fetus, usually controlled by transport channels and endocytic or diffusive processes (52). AuNPs in 4-20 nm showed ligand dependent toxicity, which interns upon further investigation, revealed due to free ligation or Au precursor salts while nanoparticles showed not cellular toxicity (53). Overall, the shape of nanoparticles is also important in addition to size in a single dimension. Cellular uptake seems to be inversely related to size (in range of 30-90 nm) but directly related to roundness of AuNPs (54). Rod shaped AuNPs appeared to have less cellular uptake efficiency in comparison to spherical one. Usually, rod shaped AuNPs show lower internalization than spherical particles albeit toxicity profiles don't differ significantly (55). Although no hard and fast rules exist to serve as starting point, screening of size of nanoparticles along with appropriate surface group is necessary to assure the safety of nanoparticles before using them in clinical practice. Table 1 cites selected major reports that explain the size dependent toxicity of AuNPs *in vitro* and *in vivo*.

Surface chemistry

The surface chemistry is a key factor governing interaction of AuNPs with the living system (44). The first and foremost consideration in selecting surface coating materials is that they should be biocompatible and non-toxic. For example, phosphine-stabilized AuNPs having size of 1.4 nm have been prepared but failed electrophysiology-based safety testing in human embryonic kidney cells, a safety test prescribed in FDA guideline (56). In addition, leaching of such surface coating materials may be problematic such as toxicity caused by cetyltrimethyl ammonium bromide CTAB, a famous stabilizing agent for AuNPs (57). The behavior of AuNPs may also be explained on the basis of corona of functional groups attached on their

surface. The toxicity of gold nanorods and nanospheres on human hepatocellular carcinoma cell line has been proven to be reduced by encapsulating the nanomaterials in silica core (58). In another work, the intracellular accumulation of AuNPs in macrophages was shown to occur in chronic exposure only. AuNPs coated with polyethylene glycol (PEG) show decreased cytotoxicity along with low intracellular accumulation (54). This was further supported by another study which demonstrated inverse relation between PEG MW on surface and cellular uptake of AuNPs (54). PEGylated nanoparticles exhibited reduced interaction with intracellular proteins which ultimately resulted in rapid expulsion of these nanoparticles from the cells (59). In another study, different AuNPs coated with ethanediamine, glucosamine, hydroxypropylamine, taurine, and PEG were prepared and internalization of these particles in the primary culture of human endothelial cells was investigated. It was found that the particles coated with ethanediamine were internalized to very high extent indicating that these particles can be studied for chronic toxicity on human endothelial cells (60).

The density of PEG coating on AuNPs has also shown to affect the binding of serum protein on the nanoparticle surface, a property which actually affects the uptake by macrophages (Figure 1). At high PEG/nm of AuNPs, the serum protein adsorption on the surface of nanoparticles decreased while at low density of PEG/nm, the adsorption of serum protein increased supporting a competitive ligand displacement mechanism for serum protein adsorption on AuNPs. High density of PEG on the surface of AuNPs resulted in increased uptake of the nanoparticles by macrophages (61). Surface coating material has also been proven to modify other toxicity parameters. Aspartate, citrate and bovine serum albumin, when used as capping material, AuNPs appeared to be non-toxic *in-vitro* against human fibroblast cells (MRC-5). They found that all the three types of AuNPs were proven to be non-cytotoxic in *in vitro* experiments against human fibroblast cell line (MRC-5) but the *in-vivo* studies in murine models showed the citrate capped AuNPs were hepatotoxic while aspartic acid capped AuNPs were hepatotoxic as well as nephrotoxic (62). Liver contains diverse families of enzymes that can catalyze many types of materials. This can explain altered biodistribution of nanoparticles *in-vivo* (63). Surface modification can also play role in colloidal

stability. Agglomeration of nanoparticles as imparted by coating material may lead to reduction in internalization, reduced renal clearance and blockade of blood vessels. Aggregation of AuNPs is mainly dependent on zeta potential imparted by ligands. Particles with positive surface charge are less prone to aggregate and presents longer stability *in-vitro* as compared to negative charge AuNPs (64). However this is inverted *in-vivo* where negatively charged proteins are electrostatically adsorbed on positive surface of AuNPs, phenomenon of opsonization, and results in aggregation-responsible for toxicity profiles and accumulation in glomerular filtration assembly and probably for nephrotoxic profile (18, 65-67).

Special Case: Oxidation Stress

Reactive oxygen species are free radicals formed inside that cells which have the potential to redox damage several intracellular processes. This mechanism is well reported for gold nanoparticles and many researchers claim it to be the key molecular event for its pharmacological activity (68). At the same time, gold nanoparticles have shown mutagenicity, genotoxicity and cytotoxicity in a number of studies and the mechanism evaluated for the cause of damage is increased reactive oxygen species (ROS). Production of ROS leads to damage in DNA resulting in genotoxicity, mutagenicity and cytotoxicity (41, 69, 70). Although some research work have also reported the toxicity of AuNPs independent of ROS production (71, 72). However, none of these studies could neglect the role of ROS. Thus, it can be stated that ROS production may not be the sole player of DNA damage and some other mechanism may also be responsible for its toxicity like leaching of Au ions from nanoparticles and complexing effect with surrounding bio-macromolecules (65, 73). Antioxidants have the ability to destroy the ROS and a large number of antioxidants have been reported which have been extensively used in the clinical practice. Ascorbic acid, glutathione and N-acetyl cysteine (a precursor of glutathione) are known antioxidants which have been known in clinical practice. If the glutathione production is genetically suppressed, the genotoxicity and cytotoxicity of AuNPs is reported to be increased (74).

Research work also supports the fact that use of antioxidants prior to or along with AuNPs has resulted in decreased ROS production and cytotoxicity. Triphenylphosphine monosulfonate,

glutathione and N-acetyl cysteine were used as antioxidants and pretreatment with these agents decreased AuNPs associated ROS production (50). In another study, the decreased level of ROS caused by dimethyl sulfoxide (DMSO) resulted in overall

increased wound healing by combination therapy of therapeutic pulsed ultrasound, AuNPs and DMSO (75). In some cases, antioxidants have been beneficial in reducing the genotoxicity induced by the oxidative stress generation (35).

Table 1. *in vitro* and *in vivo* toxicity of gold nanoparticles depending upon size

Size (nm)	Ligand*	Cell line	Dose	Toxicological effect	Reference
<i>in vitro</i> studies in cell line					
0.8, 1.2, 1.4, 1.8, 15	TPPMS, TPPTS	HeLa	250 µM	AuNPs of 1.2 nm lead to apoptosis whereas AuNPs of 1.4 nm produced necrosis. 1.4 nm AuNPs are most toxic of these	(43)
2	Quaternary ammonium	COS-1 mammalian cells	0.38-3 µM	Cationic nanoparticles are toxic	(76)
3.5	Lysine/polylysine	RAW 264.7 mouse macrophage	10-100 µM	Non-toxic and immunogenic	(77)
3.7 <10	PEG –	HeLa A549 cells	100 µM 5 µg/ml	No toxicity Nanoparticles prepared in water are non-toxic whereas those prepared in acetone induce apoptosis	(78) (79)
13.1	Citrate	Human dermal fibroblast	4 mM	Decreased cell proliferation	(80)
15	Citrate	Human alveolar macrophage (A549) cells	2000 µM	No toxicity	(81)
15, 50, 100 nm	–	Caco-2 cells	5 µg/ml	Cytotoxic, larger particles are more toxic to mitochondria	(82)
18	Citrate	HeLa	2 nM	Non-toxic	(83)
16, 26, 40, 58	(10-Mercapto-decyl)-trimethyl-ammonium bromide (TMA) for positive charge and 11-Mercaptoundecanoic acid (MUA) for negative charge	RAW 264.7 and non-phagocytic HepG2 cells	Au concentration of 10 mg/L	Positive nanoparticles show higher cytotoxicity against HepG2 cells. Negative nanoparticles show higher cytotoxicity against RAW 264.7 cells	(84)
33	CTAB and citrate	BHK21 cells of hamster kidney	120 nM	Not toxic	(85)
50	Citrate	Blood		Non toxic	(86)
90		Human prostate carcinoma (PC-3) cell	34 nM	Non-Toxic	(87)

Table 1 Continued...

100	PCL	Human umbilical vein endothelial (ECV 304) cells		Non-toxic	(88)
<i>in vivo</i> studies in animal models					
20	Arabic gum	Pigs	1.8 mg/kg	No toxicity	(89)
4, 10, 28, 58	Citrate	Mice (BALB/c)	200 mg/kg	No toxicity	(90)
3, 5, 8, 12, 17, 37, 50, 100	Citrate	Mice (BALB/c)	8 mg/kg	8-37 nm show lethality	(91)
3, 10, 50, 100	Citrate	Zebra fish	Up to 250 µM	No toxicity	(92)
15, 50, 100, 200	Citrate	Mice (ddy)	1000 mg/kg	15 and 50 nm were found in liver, kidney, heart and brain. No toxicity reported.	(93)
13	PEG	Mice (BALB/c)	4.26 mg/kg	Inflammation and apoptosis in liver	(86)
13.5	Citrate	Mice	2.2 mg/kg	Reduction in body weight and RBC count	(94)
17, 37	–	Mice (BALB/C)	8 mg/kg/week	Produce fever and altered dopamine and serotonin secretion; 17 nm particles impair learning and memory	(91)
20, 40, 80	PEG	Mice (BALB/c)	2010 mg/kg	No toxicity	(95)
18.6, 67.5	Tannic acid	Polymorphonuclear neutrophil cells	100 µM	Induction of apoptosis associated with degradation of cytoplasmic proteins and endoplasmic reticulum stress	(96)
2, 10, 25 nm and their aggregate	PVP	HeLa	0.83 nM	2 nm don't but 10 and 25 nm cause cytotoxicity. However, larger aggregates promote cell growth.	(97)
* Ligand are not toxic at this concentration when administered alone.					

SILVER NANOPARTICLES

AgNPs are widely used due to their unique properties like catalysis and sensing (98, 99). Recently, AgNPs have become focus of biomedical research due to their antimicrobial properties (100-105). AgNPs are bactericidal in nature due to multimodal pathways. Although molecular basis of bactericidal action is unknown, different studies show that AgNPs can cause lysis by arresting different processes such as cell wall synthesis, arrest mitochondrial system, ribosomes inhibition or damage to nucleic material

i.e. DNA (106-108). In addition, they can also synergize efficacy of many antibiotics and has opened new horizon to treat MDR infections (109). Now, various orthopedic devices and wound dressings are available in market with AgNPs coatings to prevent against microbial contamination of underlying wound (110). The toxicity of AgNPs is also studied and a body of literature is available in this direction. In some studies the genotoxicity of nanoparticles is well documented while in some studies contradictory effects are also reported.

AgNPs are supposed to damage mammalian cells in the same way as they do the bacterial and fungal cells.

Size and Shape

Some studies have also shown that the smaller sized AgNPs causes increased toxicity (111). This observation is supported by the fact that smaller sized particles can easily enter into the cells. However, some studies report contrasting results and role of silver nanoparticle size in toxicity is not well supported (28). Lee et al. evaluated the biodistribution of AgNPs of around 10 and 25 nm size in brain and testicles, and found it to be independent of size. However on the other hand, when Park et al. scanned biodistribution of AgNPs with significant size differences (22, 42, 71 and 323 nm), the accumulation of AgNPs in different tissues including brain and testicles was inversely related to size. The AgNPs of 323 nm were not able to diffuse in any organ (112, 113). Similarly, Hendrickson et al. have recently reported the affinity of 12 nm AgNPs *i.e.* smaller size range having more affinity to liver and kidney (114). These studies revealed size to be important factor in controlling the biodistribution of AgNPs but results are only visible when size is significantly varied. There is possibility of achieving a balance between size and pharmacology of AgNPs and minimizing its tissue accumulation which subsequently results in toxicity. Although size of AgNPs can alter biodistribution, its association with toxicity is not established. Moreover, shape of nanoparticle may also not significantly affect toxicity of AgNPs (115).

Surface chemistry

The antibiotic effects of AgNPs, although well documented, prerequisite its efficacy and clinical use to specific bacterial cells *i.e.* it should kill only bacterial cells without harming the host cells. Considerable efforts have been made in order to make AgNPs host specific. One possibility is to treat host cells with anti-oxidants e.g. N acetyl cysteine or reduced glutathione (GSH) potentiating their ability to detoxify ROS species. Cytotoxicity and genotoxicity of Ag nanoparticles is observed at concentrations much higher than MIC of AgNPs (88). Dose dependent toxicity is also observed in zebrafish models even using albumin as capping agent (116). In this way, it has been proved that the cytotoxicity and genotoxicity of host cell may be prevented by using appropriate dose of AgNPs. As

toxicity of AgNPs is mainly due to leaked Ag ions (117), organic coating is more capable to prevent leaking of Ag ions as compared to inorganic coating (118).

Just as discussed for AuNPs, intrinsic toxicity of surface coating material can also participate in overall toxicity of nanoparticles. Lu et al. conducted a comprehensive study to evaluate toxicity of AgNPs with different coating properties. They found that polyvinylpyrrolidone (PVP) coated AgNPs are more biocompatible than citrate coated nanoparticles. Interestingly, they also observed that citrate coating may undergo chemical changes during drying process rendering them more cytotoxic, genotoxic and phototoxic (115). Protein ligations on the surface of AgNPs enhanced their cellular biocompatibility and kept them dispersed in cytoplasm of fibroblast cells (119). Yang et al. determined toxicity of AgNPs with different ligands in order of Gum Arabic>PVP>citrate (28). Gum Arabic is of natural and biocompatible origin than citrate and PVP but presented greater cytotoxicity which is explained on the basis of ability of ligand to tightly cap the underlying AgNPs. Citrate has more ability to tightly ligate the Ag in nanoparticles thus poses lesser risk of leaking out of Ag ions and thus less toxicity.

Zeta potential or surface charge of AgNPs plays important role in anti-microbial potential of nanoparticles. The presence of carboxyl, amino and phosphate groups in cell wall of bacteria, gives it a net negative charge which repels negatively charges AgNPs like citrate (-40 mV) and PVP (-12 mV). AgNPs capped with branched polyethyleneimine (+39 mV) showed greater bacterial interaction (120). AgNPs with near to zero *i.e.* neutral zeta potential appeared to be less toxic as compared to negatively charges AgNPs. Park et al. synthesized AgNPs with 0.91 mV zeta potential and they showed EC₂₀ (concentration for 20 % cell death and 80 % viable) of 1.6 µg/ml against 5000 cells/ml of RAW264.7 (121). While Park et al. synthesized AgNPs with -47 mV zeta potential and its EC₂₀ was around 0.18 µg/ml against 3×10^6 cells/ml of RAW264.7 (122). It can be deduced from these two independent studies that more negative zeta potential greatly enhance the cytotoxicity potential of AgNPs, excluding the effect of size and ligands.

Special Case: Ionization of Silver

Genotoxic potential is reported in many studies (26, 87, 121, 123) and the mechanism is supposed to be ionization of AgNPs by Trojan horse type

mechanism leading to production of Ag^{+2} and ROS (117). Stored AgNPs formulation was proven to be more toxic than freshly formulated preparation. Reason for this increased toxicity is the erosion of surface coating or dissolution/leaking of silver to Ag^+ ions (124). If these particles are to be marketed for clinical use for therapeutic application, it is very difficult to make fresh AgNPs for use as antibacterial agent. Similarly, no study is present to investigate the dissolution of AgNPs when it is absorbed in the systemic circulation. If the dissolution of AgNPs takes place *in vivo*, it would cause systemic toxicity which may over weigh the beneficial effect. This ROS produces oxidative stress which ultimately leads to genotoxicity and cytotoxicity of the cell. In some studies, oxidative stress is associated with reduced amount of glutathione present in the cell (125). But some contradictory studies are also documented as in one experiment; AgNPs were injected in group of mice for 28 days and any mutation on the cells of bone were investigated by hematological studies and no significant damage to the blood cells were documented (126). Similarly, nanoparticles were administered in mice by inhalation for twenty eight days and no significant change in blood chemistry was reported (127).

Over all conclusion, from so far reports on toxicity of AgNPs is to control the dissolution and leaking of Ag ions from AgNPs by size or surface ligation. More efficient surface ligation with tightly packed ligands on nanoparticles surface will prevent the Ag ions leaking, enhancing its colloidal stability and thus reducing toxicity.

IRON NANOPARTICLES

Iron is considered one of the most inert materials used in nanotechnology. It is a common component of many biological systems such as bio-imaging, blood circulation (128, 129), energy production (130), enzyme catalysis (131, 132) and immune system (133). Iron oxide nanoparticles (IONP) have drawn considerable attention in medical field. Just as discussed for gold and silver, iron showed improved properties at nanoscale. They are widely investigated for diagnostics, drug delivery and dual function modalities *i.e.* therapeutic and MRI diagnostic. This paramagnetic behavior can be exploited in MRI which use strong magnetic field for diagnosis of various lesions and pathological changes in the body. MRI uses a combination of magnetic field radiofrequency pulse to image body organs containing IONP. They improve contrast of image

and ensure imaging of target organs with particular safety for pediatrics and geriatrics patients (134-138).

Therapeutic use of IONP is mostly related to its applications in drug delivery. It can load drug and target it to specific site under the influence of magnetic field. IONP are usually intravenously administered to patient for diagnosis and targeting. IONP can be targeted to a specific area by applying external magnetic field directly over tumor affected body part (Figure 2). IONP based targeting with magnetic field has been comprehensively reviewed elsewhere by (139) and readers interested in this aspect are encouraged to read their review article. This will localize nanoparticles in this region when they reach with blood circulation. Another strategy is to use targeting (140-142). IONP based hyperthermia is utilized for controlling the release of the drug from the temperature sensitive micelles due to phase change in micelles. When micelles are deformed, drug is released in the target tissue (11, 143). In another study the synergistic effects of the hyperthermia and chemotherapeutic drugs has been reported on various cell lines (144). These site specific retention characteristics of IONP is also utilized in hyperthermia mediated treatment of tumor. When IONP are exposed to alternating magnetic field, heat is generated. Heating tumor mass up to 45°C will lead to apoptosis whereas heating above it may cause necrosis. Recently, it has also been used for thermotherapy or thermos- ablation of tumor tissues (145). IONP are leading paradigm in theranostic nanoparticles due to above mentioned diagnostic and therapeutic uses. One example is image guided therapy in which IONP can locate cancer and kill them with loaded drug or burn them by heat produced after alternating magnetic field application (23, 24).

Thus, IONP will not only prevent the unwanted effects of the anti-cancer drugs but it will also augment the cytotoxicity of these drugs. Like Ag and AuNPs, the toxicity of IONP is subjected to considerable debate with results depending upon various factors. In the work of (146-149) the genotoxicity of IONP is reported. Among these results the effect of IONP on human skin and lung cell lines were of considerable importance as drug carrier in humans (146). Iron may exist as ferrous (+2) or ferric (+3) form in NPs and both oxidation states show similar physicochemical properties. Fe_2O_3 and Fe_3O_4 nanoparticles may present different level of interaction with biological tissues and

relative abundance of these materials may be of significant importance in in-vivo toxicity studies (147).

Size

IONP which are used for diagnostics are usually smaller than 10 nm because superparamagnetic properties can only be achieved at such small size. However, this size can lead to removal of IONP after they are settled in tumor mass via leaky vasculature. Thus, passive targeting by EPR effect may not be feasible for IONP. Their toxicity may not be related to its size as shown by many studies. Thus, size of IONP may not be of much significance except for its magnetic characteristics that are usually found to be safe (150).

Surface chemistry

IONP have been reported with various surface coatings materials. In addition to above discussed materials for biocompatibility or penetration enhancement, they have been combined with other

metals to form novel structures with modified magnetic and heating properties (151). However, toxicity of IONP is dependent upon materials forming the shell and we have not discussed nanoparticles with non-iron metallic shells. IONP have been prepared with PEG and folic acid coating for enhancing their release only in cancerous cells. The results obtained in these experiments are of substantial importance as tumor mass was decreased up to 10 fold than control group. In another study, the IONP were coated with different materials and their toxicity was evaluated. Results clearly revealed dependence of toxicity on surface ligation. It was established that the surface of IONP could be manipulated to alter the endocytosis of nanoparticles and their subsequent toxicity (152). Similarly, coating of IONP nanoparticles with three very closely related carbohydrates *i.e.* glucose, lactose and maltose resulted in very different behavior in human cell line suggesting that the effect of surface coating will markedly affect nanoparticles fate *in vivo* (153).




Figure 2. Enhanced permeability and retention (EPR) effect under magnetic field. Nanoparticles are accumulated in tumor tissues due to leaky vasculature. Non-stealth nanoparticles are rapidly cleared through kidney and lungs whereas stealth nanoparticles can escape this elimination step. Nanoparticles accumulation in tumor is further enhanced after external application of magnetic field (produced with permission from (138)).

Soensen et al. performed a series of studies to find interdependence of nanoparticles coating and toxicity. They found that toxicity may be observed with materials that are intrinsically toxic (154). Later, Sorensen et al. showed that cellular uptake of oxide nanoparticles is also influenced by surface coating. Thus, toxicity of IONP is mainly controlled by extent of internalization and number of nanoparticles per cells (155, 156).

When coating is not homogenous on nanoparticles, the resultant nanoparticles will present coated and uncoated surfaces that may pose different toxicity issues (157). In some studies, the mechanism seemed to be responsible for the genotoxicity was the ROS generation (158). In other studies, contradictory results were observed including peroxidase like activity of nanoparticles to reduce oxidative stress (159, 160). Thus, involvement of ROS in IONP toxicity remains controversial. In the case of IONP, we lack the data in which N acetyl cysteine or glutathione could be used for reduction of ROS generation and prevention of DNA damage could be achieved. Although the mechanism responsible for the toxicity of IONP is suggested to be ROS generation in (159) so we suggest that pretreatment with N acetyl cysteine if lead to decreased toxicity of IONP, will indicate ROS dependency of IONP for toxicity. We should also consider the factor of iron overload, when considering them for clinical application, the problem which is commonly encountered in the patients of thalassemia (161). The metal may dissolve inside the body and lead to hemosiderosis *i.e.* accumulation of iron in various body organs especially liver. If such condition appears, patient may be treated with iron chelator like desferrioxamine (162).

Special case: Interference with Intracellular Signaling

IONP have shown to inhibit differentiation of stem cells. These effects have been observed with dextran coated IONP when used during labelling of mesenchymal stem cells (163, 164). Another study found that IONP can suppress formation of new blood vessels from progenitor cells (165). These

studies support the interference of IONP with different intracellular pathways leading to altered cell response to growth factors (157). However, these effects are also dependent upon intracellular concentration of IONP and many strategies aimed to reduce IONP dose may serve to overcome these problems (166). In magnetic field hyperthermia, tumor cells respond to applied hyperthermia by producing heat shock proteins. Although their function is to prevent cell damage resulting from heat, they are recognized by human immune system resulting in anti-tumoral immune response (167). However, no link has yet been found between these immunomodulatory effects and IONP and these vaccine like effects are attributed to hyperthermia (168).

CONCLUSION

Relatively inert materials such as gold, silver and iron can show toxicity at nanoscale as the mechanism of nano-toxicity is dependent markedly upon size and surface chemistry, which intern, is further associated with degree of internalization in cells or leaking. Thus, enhancing the colloidal stability and purity of AuNPs, AgNPs and IONPs can lead to reduction in their toxicity, making their clinical application possible. Surface coating material may modulate nanoparticles toxicity either directly or by altering penetration in cell. After internalization, nanoparticles can interact in dose and colloidal stability dependent fashion with different intracellular systems such as mitochondria, ribosomes and chromosomes. AuNPs and AgNPs have shown to induce production of ROS that can arrest different cell processes. On the other hand, IONP have shown to modulate intracellular signaling pathways, thus altering different cell processes leading to cell death. Careful selection of coating materials and comprehensive characterization of surface coated nanoparticles is prerequisite for clinical applications. We further stress the need of uniform guidelines of test procedures that will aid in systematic analysis of toxicity of different nanomaterials.




Figure 3. Mechanism of toxicity after internalization into cell, a) gold nanoparticles cause toxicity by physical interaction and ROS production, b) silver nanoparticles cause toxicity by physical interactions, silver ions (Ag^{+2}) and ROS production and c) iron oxide nanoparticles intracellular toxicity by ROS mediated oxidative stress.

REFERENCES

1. Sattler KD. Handbook of nanophysics: nanoparticles and quantum dots: CRC press; 2010.
2. Khan FA. Biotechnology fundamentals: CRC Press; 2011.
3. Khan IU, Serra CA, Anton N, Vandamme TF. Production of nanoparticle drug delivery systems with microfluidics tools. Expert opinion on drug

- delivery. 2015;12(4):547-62. doi: 10.1517/17425247.2015.974547.
4. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. *Cancer*. 2006;107(3):459-66.
 5. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2012;8(2):147-66. doi: 10.1016/j.nano.2011.05.016
 6. Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? *Theranostics*. 2014;4(1):81. doi: 10.7150/thno.7193.
 7. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy *in vivo*. *Proceedings of the National Academy of Sciences*. 2011;108(5):1850-5. doi: 10.1073/pnas.1011379108.
 8. Serra L, Doménech J, Peppas NA. Engineering design and molecular dynamics of mucoadhesive drug delivery systems as targeting agents. *European journal of pharmaceutics and biopharmaceutics*. 2009;71(3):519-28. doi: 10.1016/j.ejpb.2008.09.022.
 9. Cheng Y, Dai Q, Morshed RA, Fan X, Wegscheid ML, Wainwright DA, et al. Blood-Brain Barrier Permeable Gold Nanoparticles: An Efficient Delivery Platform for Enhanced Malignant Glioma Therapy and Imaging. *Small*. 2014;10(24):5137-50. doi: 10.1002/sml.201400654..
 10. Hernández-Pedro NY, Rangel-López E, Magaña-Maldonado R, de la Cruz VP, Santamaría del Angel A, Pineda B, et al. Application of nanoparticles on diagnosis and therapy in gliomas. *BioMed research international*. 2013;2013. doi: 10.1155/2013/351031.
 11. Madni A, Sarfraz M, Rehman M, Ahmad M, Akhtar N, Ahmad S, et al. Liposomal drug delivery: a versatile platform for challenging clinical applications. *Journal of Pharmacy & Pharmaceutical Sciences*. 2014;17(3):401-26.
 12. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. *Pharmacological reviews*. 2001;53(2):283-318.
 13. Prabakaran M, Grailer JJ, Pilla S, Steeber DA, Gong S. Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery. *Biomaterials*. 2009;30(30):6065-75. doi: 10.1016/j.biomaterials.2009.07.048
 14. Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. *Clinical cancer research*. 2008;14(5):1310-6.
 15. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. *Nano letters*. 2009;9(5):1909-15. doi: 10.1021/nl900031y.
 16. Hayashi K, Nakamura M, Sakamoto W, Yogo T, Miki H, Ozaki S, et al. Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. *Theranostics*. 2013;3(6):366. doi: 10.7150/thno.5860.
 17. Herzog F, Clift MJ, Piccapietra F, Behra R, Schmid O, Petri-Fink A, et al. Exposure of silver-nanoparticles and silver-ions to lung cells *in vitro* at the air-liquid interface. *Particle and fibre toxicology*. 2013;10(1):1. doi: 10.1186/1743-8977-10-11.
 18. Javed I, Hussain SZ, Shahzad A, Khan JM, Rehman M, Usman F, et al. Lecithin-Gold Hybrid Nanocarriers as Efficient and pH Selective Vehicles for Oral Delivery of Diacerein—In-Vitro and In-Vivo Study. *Colloids and Surfaces B: Biointerfaces*. 2016. doi: 10.1016/j.colsurfb.2016.01.022
 19. Li L, Jiang W, Luo K, Song H, Lan F, Wu Y, et al. Superparamagnetic iron oxide nanoparticles as MRI contrast agents for non-invasive stem cell labeling and tracking. *Theranostics*. 2013;3(8):595-615. doi: 10.7150/thno.5366.
 20. Hoskins C, Min Y, Gueorguieva M, McDougall C, Volovick A, Prentice P, et al. Hybrid gold-iron oxide nanoparticles as a multifunctional platform for biomedical application. *J Nanobiotechnol*. 2012;10:27.
 21. Guo Y, Zhang Z, Kim D-H, Li W, Nicolai J, Procissi D, et al. Photothermal ablation of pancreatic cancer cells with hybrid iron-oxide core gold-shell nanoparticles. *International journal of nanomedicine*. 2013;8:3437. doi: 10.2147/IJN.S47585.
 22. Larginho M, Baptista PV. Gold and silver nanoparticles for clinical diagnostics—from genomics to proteomics. *Journal of proteomics*. 2012;75(10):2811-23. doi: 10.1016/j.jprot.2011.11.007.
 23. Yang K, Hu L, Ma X, Ye S, Cheng L, Shi X, et al. Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. *Advanced materials*. 2012;24(14):1868-72. doi: 10.1002/adma.201104964.
 24. Ling D, Lee N, Hyeon T. Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. *Accounts of chemical research*. 2015;48(5):1276-85. doi: 10.1021/acs.accounts.5b00038.
 25. Li YF, Chen C. Fate and Toxicity of Metallic and Metal-Containing Nanoparticles for Biomedical Applications. *Small*. 2011;7(21):2965-80. doi: 10.1002/sml.201101059.
 26. Katsnelson BA, Privalova LI, Gurvich VB, Makeyev OH, Shur VY, Beikin YB, et al. Comparative *in vivo* assessment of some adverse bioeffects of

- equidimensional gold and silver nanoparticles and the attenuation of nanosilver's effects with a complex of innocuous bioprotectors. *International journal of molecular sciences*. 2013;14(2):2449-83. doi: 10.3390/ijms14022449.
27. Bondarenko O, Juganson K, Ivask A, Kasemets K, Mortimer M, Kahru A. Toxicity of Ag, CuO and ZnO nanoparticles to selected environmentally relevant test organisms and mammalian cells in vitro: a critical review. *Archives of toxicology*. 2013;87(7):1181-200. doi: 10.1007/s00204-013-1079-4.
 28. Yang X, Gondikas AP, Marinakos SM, Auffan M, Liu J, Hsu-Kim H, et al. Mechanism of silver nanoparticle toxicity is dependent on dissolved silver and surface coating in *Caenorhabditis elegans*. *Environmental science & technology*. 2011;46(2):1119-27. doi: 10.1021/es202417t.
 29. Walkey CD, Olsen JB, Guo H, Emili A, Chan WC. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. *Journal of the American Chemical Society*. 2012;134(4):2139-47. doi: 10.1021/ja2084338.
 30. Walz D, DiMartino M, Griswold D. Comparative pharmacology and biological effects of different gold compounds. *The Journal of rheumatology Supplement*. 1981;8:54-60.
 31. Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? *Journal of nanoparticle research*. 2010;12(7):2313-33.
 32. Rengan AK, Bukhari AB, Pradhan A, Malhotra R, Banerjee R, Srivastava R, et al. *In vivo* Analysis of Biodegradable Liposome Gold Nanoparticles as Efficient Agents for Photothermal Therapy of Cancer. *Nano letters*. 2015. doi: 10.1021/nl5045378.
 33. Bastús NG, Sánchez-Tilló E, Pujals S, Farrera C, Kogan MJ, Giral E, et al. Peptides conjugated to gold nanoparticles induce macrophage activation. *Molecular immunology*. 2009;46(4):743-8. doi: 10.1016/j.molimm.2008.08.277.
 34. Ghosh PS, Kim C-K, Han G, Forbes NS, Rotello VM. Efficient gene delivery vectors by tuning the surface charge density of amino acid-functionalized gold nanoparticles. *Acs Nano*. 2008;2(11):2213-8. doi: 10.1021/nm800507t.
 35. Han G, Ghosh P, Rotello VM. Functionalized gold nanoparticles for drug delivery. *Nanomedicine*. 2007;2(1):113-23.
 36. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. *Drug discovery today*. 2006;11(17):812-8.
 37. Bardhan R, Lal S, Joshi A, Halas NJ. Theranostic nanoshells: from probe design to imaging and treatment of cancer. *Accounts of chemical research*. 2011;44(10):936-46. doi: 10.1021/ar200023x.
 38. Downs TR, Crosby ME, Hu T, Kumar S, Sullivan A, Sarlo K, et al. Silica nanoparticles administered at the maximum tolerated dose induce genotoxic effects through an inflammatory reaction while gold nanoparticles do not. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*. 2012;745(1):38-50. Doi: 10.1016/j.mrgentox.2012.03.012.
 39. Schulz M, Ma-Hock L, Brill S, Strauss V, Treumann S, Gröters S, et al. Investigation on the genotoxicity of different sizes of gold nanoparticles administered to the lungs of rats. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*. 2012;745(1):51-7. doi: 10.1016/j.mrgentox.
 40. Jain A, Mishra SK, Vuddanda PR, Singh SK, Singh R, Singh S. Targeting of diacerein loaded lipid nanoparticles to intra-articular cartilage using chondroitin sulfate as homing carrier for treatment of osteoarthritis in rats. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2014;10(5):1031-40. doi: 10.1016/j.nano.2014.01.008.
 41. Paino IMM, Marangoni VS, de Oliveira RdCS, Antunes LMG, Zucolotto V. Cyto and genotoxicity of gold nanoparticles in human hepatocellular carcinoma and peripheral blood mononuclear cells. *Toxicology letters*. 2012;215(2):119-25. doi: 10.1016/j.toxlet.2012.09.025.
 42. Taylor U, Barchanski A, Garrels W, Klein S, Kues W, Barcikowski S, et al. Toxicity of gold nanoparticles on somatic and reproductive cells. *Nano-Biotechnology for Biomedical and Diagnostic Research: Springer*; 2012. p. 125-33. doi: 10.1007/978-94-007-2555-3_12.
 43. Pan Y, Neuss S, Leifert A, Fischler M, Wen F, Simon U, et al. Size-dependent cytotoxicity of gold nanoparticles. *Small*. 2007;3(11):1941-9.
 44. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. *Proceedings of the National Academy of Sciences*. 2008;105(38):14265-70. doi: 10.1073/pnas.0805135105.
 45. Wen F, Dong Y, Feng L, Wang S, Zhang S, Zhang X. Horseradish peroxidase functionalized fluorescent gold nanoclusters for hydrogen peroxide sensing. *Analytical chemistry*. 2011;83(4):1193-6. doi: 10.1021/ac1031447.
 46. Kawasaki H, Hamaguchi K, Osaka I, Arakawa R. pH-Dependent synthesis of pepsin-mediated gold nanoclusters with blue green and red fluorescent emission. *Advanced Functional Materials*. 2011;21(18):3508-15. Doi: 10.1002/adfm.201100886.
 47. Chevrier DM, Chatt A, Zhang P. Properties and applications of protein-stabilized fluorescent gold nanoclusters: short review. *Journal of*

- Nanophotonics. 2012;6(1):064504-1--16. doi:10.1117/1.JNP.6.064504.
48. Chen W-Y, Lan G-Y, Chang H-T. Use of fluorescent DNA-templated gold/silver nanoclusters for the detection of sulfide ions. *Analytical chemistry*. 2011;83(24):9450-5. doi: 10.1021/ac202162u.
 49. Thomas A. Blue emitting gold nanoclusters templated by poly-cytosine DNA at low pH and poly-adenine DNA at neutral pH. *Chemical Communications*. 2012;48(54):6845-7. doi: 10.1039/c2cc32841k.
 50. Pan Y, Leifert A, Ruau D, Neuss S, Bornemann J, Schmid G, et al. Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. *Small*. 2009;5(18):2067-76. doi: 10.1002/sml.200900466.
 51. Malay AD, Heddle JG, Tomita S, Iwasaki K, Miyazaki N, Sumitomo K, et al. Gold nanoparticle-induced formation of artificial protein capsids. *Nano letters*. 2012;12(4):2056-9. doi: 10.1021/nl3002155.
 52. Semmler-Behnke M, Lipka J, Wenk A, Hirn S, Schäffler M, Tian F, et al. Size dependent translocation and fetal accumulation of gold nanoparticles from maternal blood in the rat. *Particle and fibre toxicology*. 2014;11(1):1-12. doi: 10.1186/s12989-014-0033-9.
 53. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. *Small*. 2005;1(3):325-7. Doi: 10.1002/sml.200400093.
 54. Malugin A, Ghandehari H. Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: a comparative study of rods and spheres. *Journal of Applied Toxicology*. 2010;30(3):212-7. doi: 10.1002/jat.1486.
 55. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. *Nano letters*. 2006;6(4):662-8.
 56. Leifert A, Pan Y, Kinkeldy A, Schiefer F, Setzler J, Scheel O, et al. Differential hERG ion channel activity of ultrasmall gold nanoparticles. *Proceedings of the National Academy of Sciences*. 2013;110(20):8004-9. doi: 10.1073/pnas.1220143110.
 57. Alkilany AM, Nagaria PK, Hexel CR, Shaw TJ, Murphy CJ, Wyatt MD. Cellular uptake and cytotoxicity of gold nanorods: molecular origin of cytotoxicity and surface effects. *Small*. 2009;5(6):701-8. doi: 10.1002/sml.200801546.
 58. Zeng Q, Zhang Y, Ji W, Ye W, Jiang Y, Song J. Inhibition of cellular toxicity of gold nanoparticles by surface encapsulation of silica shell for hepatocarcinoma cell application. *ACS applied materials & interfaces*. 2014;6(21):19327-35. doi: 10.1021/am505417v.
 59. Oh N, Park J-H. Surface chemistry of gold nanoparticles mediates their exocytosis in macrophages. *ACS nano*. 2014;8(6):6232-41. doi: 10.1021/nn501668a.
 60. Freese C, Gibson MI, Klok H-A, Unger RE, Kirkpatrick CJ. Size-and coating-dependent uptake of polymer-coated gold nanoparticles in primary human dermal microvascular endothelial cells. *Biomacromolecules*. 2012;13(5):1533-43. doi: 10.1021/bm300248u.
 61. Das S, Debnath N, Mitra S, Datta A, Goswami A. Comparative analysis of stability and toxicity profile of three differently capped gold nanoparticles for biomedical usage. *Biometals*. 2012;25(5):1009-22. doi: 10.1007/s10534-012-9567-1.
 62. Kreyling WG, Abdelmonem AM, Ali Z, Alves F, Geiser M, Haberl N, et al. *In vivo* integrity of polymer-coated gold nanoparticles. *Nature nanotechnology*. 2015. doi: 10.1038/nnano.2015.111.
 63. Rehman M, Asadullah Madni AI, Khan WS, Khan MI, Mahmood MA, Ashfaq M, et al. Solid and liquid lipid-based binary solid lipid nanoparticles of diacerein: in vitro evaluation of sustained release, simultaneous loading of gold nanoparticles, and potential thermoresponsive behavior. *International journal of nanomedicine*. 2015;10:2805. doi: 10.2147/IJN.S67147.
 64. Kim S, Jang Y, Yoon KY, Park J. Surface engineered gold nanoparticles through highly stable metal-surfactant complexes. *Journal of colloid and interface science*. 2016;464:110-6. doi: 10.1016/j.jcis.2015.10.034.
 65. Wang B, Feng W, Zhao Y, Chai Z. Metallomics insights for *in vivo* studies of metal based nanomaterials. *Metallomics*. 2013;5(7):793-803. doi: 10.1039/c3mt00093a.
 66. Vinluan III RD, Zheng J. Serum protein adsorption and excretion pathways of metal nanoparticles. *Nanomedicine*. 2015;10(17):2781-94. doi: 10.2217/nnm.15.97.
 67. Mahmoud NN, Al-Qaoud KM, Al-Bakri AG, Alkilany AM, Khalil EA. Colloidal stability of gold nanorod solution upon exposure to excised human skin: Effect of surface chemistry and protein adsorption. *The international journal of biochemistry & cell biology*. 2016. doi: 10.1016/j.biocel.2016.02.020.
 68. Abdelhalim M, Jarrar BM. Histological alterations in the liver of rats induced by different gold nanoparticle sizes, doses and exposure duration. *J Nanobiotechnology*. 2012;10(5):350. doi: 10.1186/1477-3155-10-5.
 69. Guglielmo CD, Lapuente JD, Porredon C, Ramos-López D, Sendra J, Borràs M. In vitro safety toxicology data for evaluation of gold nanoparticles-chronic cytotoxicity, genotoxicity and uptake.

- Journal of nanoscience and nanotechnology. 2012;12(8):6185-91.
70. Chuang S-M, Lee Y-H, Liang R-Y, Roam G-D, Zeng Z-M, Tu H-F, et al. Extensive evaluations of the cytotoxic effects of gold nanoparticles. *Biochimica et Biophysica Acta (BBA)-General Subjects*. 2013;1830(10):4960-73. doi: 10.1016/j.bbagen.2013.06.025.
 71. Love SA, Thompson JW, Haynes CL. Development of screening assays for nanoparticle toxicity assessment in human blood: preliminary studies with charged Au nanoparticles. *Nanomedicine*. 2012;7(9):1355-64.
 72. Zhao Y, Gu X, Ma H, He X, Liu M, Ding Y. Association of glutathione level and cytotoxicity of gold nanoparticles in lung cancer cells. *The Journal of Physical Chemistry C*. 2011;115(26):12797-802. Doi: 10.1021/jp2025413.
 73. Sabella S, Carney RP, Brunetti V, Malvindi MA, Al-Juffali N, Vecchio G, et al. A general mechanism for intracellular toxicity of metal-containing nanoparticles. *Nanoscale*. 2014;6(12):7052-61. Doi: 10.1039/C4NR01234H.
 74. Silveira PCL, Victor EG, Notoya FdS, Scheffer DdL, Silva Ld, Cantú RB, et al. Effects of phonophoresis with gold nanoparticles on oxidative stress parameters in a traumatic muscle injury model. *Drug delivery*. 2014(0):1-7. doi: 10.3109/10717544.2014.923063.
 75. Taleb A, Russier V, Courty A, Pileni M. Collective optical properties of silver nanoparticles organized in two-dimensional superlattices. *Physical Review B*. 1999;59(20):13350. Doi: 10.1103/PhysRevB.59.13350.
 76. Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. *Bioconjugate chemistry*. 2004;15(4):897-900.
 77. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. *Langmuir*. 2005;21(23):10644-54.
 78. Gu Y-J, Cheng J, Lin C-C, Lam YW, Cheng SH, Wong W-T. Nuclear penetration of surface functionalized gold nanoparticles. *Toxicology and applied Pharmacology*. 2009;237(2):196-204. doi: 10.1016/j.taap.2009.03.009.
 79. Di Bucchianico S, Migliore L, Marsili P, Vergari C, Giammanco F, Giorgetti E. Cyto-and genotoxicity assessment of Gold nanoparticles obtained by laser ablation in A549 lung adenocarcinoma cells. *Journal of Nanoparticle Research*. 2015;17(5):1-14. doi: 10.1007/s11051-015-3023-4.
 80. Pernodet N, Fang X, Sun Y, Bakhtina A, Ramakrishnan A, Sokolov J, et al. Adverse effects of citrate/gold nanoparticles on human dermal fibroblasts. *Small*. 2006;2(6):766-73.
 81. Brandenberger C, Rothen-Rutishauser B, Mühlfeld C, Schmid O, Ferron G, Maier K, et al. Effects and uptake of gold nanoparticles deposited at the air-liquid interface of a human epithelial airway model. *Toxicology and applied pharmacology*. 2010;242(1):56-65. doi: 10.1016/j.taap.2009.09.014.
 82. Yao M, He L, McClements DJ, Xiao H. Uptake of Gold Nanoparticles by Intestinal Epithelial Cells: Impact of Particle Size on Their Absorption, Accumulation, and Toxicity. *Journal of agricultural and food chemistry*. 2015;63(36):8044-9. doi: 10.1021/acs.jafc.5b03242.
 83. Khan JA, Pillai B, Das TK, Singh Y, Maiti S. Molecular effects of uptake of gold nanoparticles in HeLa cells. *Chembiochem*. 2007;8(11):1237-40.
 84. Liu X, Huang N, Li H, Jin Q, Ji J. Surface and size effects on cell interaction of gold nanoparticles with both phagocytic and nonphagocytic cells. *Langmuir*. 2013;29(29):9138-48. doi: 10.1021/la401556k.
 85. Patra HK, Banerjee S, Chaudhuri U, Lahiri P, Dasgupta AK. Cell selective response to gold nanoparticles. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2007;3(2):111-9.
 86. Cho W-S, Cho M, Jeong J, Choi M, Cho H-Y, Han BS, et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. *Toxicology and applied pharmacology*. 2009;236(1):16-24. doi: 10.1016/j.taap.2008.12.023.
 87. Song M-F, Li Y-S, Kasai H, Kawai K. Metal nanoparticle-induced micronuclei and oxidative DNA damage in mice. *Journal of clinical biochemistry and nutrition*. 2012;50(3):211-6. doi: 10.3164/jcfn.11-70.
 88. Asharani P, Wu YL, Gong Z, Valiyaveetil S. Toxicity of silver nanoparticles in zebrafish models. *Nanotechnology*. 2008;19(25):255102. doi: 10.1088/0957-4484/19/25/255102.
 89. Kattumuri V, Katti K, Bhaskaran S, Boote EJ, Casteel SW, Fent GM, et al. Gum Arabic as a Phytochemical Construct for the Stabilization of Gold Nanoparticles: *In vivo* Pharmacokinetics and X-ray-Contrast-Imaging Studies. *Small*. 2007;3(2):333-41.
 90. Hillyer JF, Albrecht RM. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. *Journal of pharmaceutical sciences*. 2001;90(12):1927-36.
 91. Chen Y-S, Hung Y-C, Liao I, Huang GS. Assessment of the *in vivo* toxicity of gold nanoparticles. *Nanoscale research letters*. 2009;4(8):858-64. doi: 10.1007/s11671-009-9334-6.
 92. Bar-Ilan O, Albrecht RM, Fako VE, Furgeson DY. Toxicity assessments of multisized gold and silver nanoparticles in zebrafish embryos. *Small*. 2009;5(16):1897-910. doi: 10.1002/sml.200801716.

93. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. *Colloids and Surfaces B: Biointerfaces*. 2008;66(2):274-80. doi: 10.1016/j.colsurfb.2008.07.004.
94. Zhang X-D, Wu H-Y, Wu D, Wang Y-Y, Chang J-H, Zhai Z-B, et al. Toxicologic effects of gold nanoparticles *in vivo* by different administration routes. *International journal of nanomedicine*. 2010;5:771-81. doi: 10.2147/IJN.S8428.
95. Zhang G, Yang Z, Lu W, Zhang R, Huang Q, Tian M, et al. Influence of anchoring ligands and particle size on the colloidal stability and *in vivo* biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. *Biomaterials*. 2009;30(10):1928-36. doi: 10.1016/j.biomaterials.2008.12.038.
96. Noël C, Simard J-C, Girard D. Gold nanoparticles induce apoptosis, endoplasmic reticulum stress events and cleavage of cytoskeletal proteins in human neutrophils. *Toxicology in Vitro*. 2016;31:12-22. doi: 10.1016/j.tiv.2015.11.003.
97. Cui W, Li J, Zhang Y, Rong H, Lu W, Jiang L. Effects of aggregation and the surface properties of gold nanoparticles on cytotoxicity and cell growth. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2012;8(1):46-53. doi: 10.1016/j.nano.2011.05.005.
98. Jiang Z-J, Liu C-Y, Sun L-W. Catalytic properties of silver nanoparticles supported on silica spheres. *The Journal of Physical Chemistry B*. 2005;109(5):1730-5.
99. Kim JS, Kuk E, Yu KN, Kim J-H, Park SJ, Lee HJ, et al. Antimicrobial effects of silver nanoparticles. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2007;3(1):95-101.
100. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramírez JT, et al. The bactericidal effect of silver nanoparticles. *Nanotechnology*. 2005;16(10):2346. doi: 10.1088/0957-4484/16/10/059.
101. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on *E. coli* as a model for Gram-negative bacteria. *Journal of colloid and interface science*. 2004;275(1):177-82. doi:10.1016/j.jcis.2004.02.012.
102. Kim K-J, Sung WS, Moon S-K, Choi J-S, Kim JG, Lee DG. Antifungal effect of silver nanoparticles on dermatophytes. *J Microbiol Biotechnol*. 2008;18(8):1482-4.
103. Ip M, Lui SL, Poon VK, Lung I, Burd A. Antimicrobial activities of silver dressings: an *in vitro* comparison. *Journal of medical microbiology*. 2006;55(1):59-63. doi: 10.1099/jmm.0.46124-0.
104. Samuel U, Guggenbichler J. Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter. *International Journal of Antimicrobial Agents*. 2004;23:75-8. doi: 10.1016/j.ijantimicag.2003.12.004
105. Fayaz AM, Balaji K, Girilal M, Yadav R, Kalaichelvan PT, Venketesan R. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gram-negative bacteria. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2010;6(1):103-9. doi:10.1016/j.nano.2009.04.006.
106. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against *Staphylococcus aureus* and *Escherichia coli*. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2007;3(2):168-71. doi:10.1016/j.nano.2007.02.001.
107. Lara HH, Ayala-Núñez NV, Turrent LdCI, Padilla CR. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. *World Journal of Microbiology and Biotechnology*. 2010;26(4):615-21. Doi: 10.1007/s11274-009-0211-3.
108. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. *Biotechnology advances*. 2009;27(1):76-83. doi:10.1016/j.biotechadv.2008.09.002.
109. Brennan S, Fhoghlú CN, Devitt B, O'Mahony F, Brabazon D, Walsh A. Silver nanoparticles and their orthopaedic applications. *Bone & Joint Journal*. 2015;97(5):582-9. doi: 10.1302/0301-620X.97B5.33336.
110. Liu W, Wu Y, Wang C, Li HC, Wang T, Liao CY, et al. Impact of silver nanoparticles on human cells: effect of particle size. *Nanotoxicology*. 2010;4(3):319-30. doi: 10.3109/17435390.2010.483745.
111. Lu W, Senapati D, Wang S, Tovmachenko O, Singh AK, Yu H, et al. Effect of surface coating on the toxicity of silver nanomaterials on human skin keratinocytes. *Chemical physics letters*. 2010;487(1):92-6. doi:10.1016/j.cplett.2010.01.027.
112. Park E-J, Bae E, Yi J, Kim Y, Choi K, Lee SH, et al. Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. *Environmental toxicology and pharmacology*. 2010;30(2):162-8. doi: 10.1016/j.etap.2010.05.004.
113. Lee JH, Kim YS, Song KS, Ryu HR, Sung JH, Park JD, et al. Biopersistence of silver nanoparticles in tissues from Sprague–Dawley rats. *Particle and fibre toxicology*. 2013;10(1):1. doi: 10.1186/1743-8977-10-36.
114. Hendrickson OD, Klochkov SG, Novikova OV, Bravova IM, Shevtsova EF, Safenkova IV, et al. Toxicity of nanosilver in intragastric studies: Biodistribution and metabolic effects. *Toxicology letters*. 2016;241:184-92. doi: 10.1016/j.toxlet.2015.11.018.

115. Hackenberg S, Scherzed A, Kessler M, Hummel S, Technau A, Froelich K, et al. Silver nanoparticles: evaluation of DNA damage, toxicity and functional impairment in human mesenchymal stem cells. *Toxicology letters*. 2011;201(1):27-33. doi: 10.1016/j.toxlet.2010.12.001.
116. Kim HR, Park YJ, Shin DY, Oh SM, Chung KH. Appropriate in vitro methods for genotoxicity testing of silver nanoparticles. *Environmental health and toxicology*. 2013;28:e2013003. doi: 10.5620/eht.2013.28.e2013003.
117. Kittler S, Greulich C, Diendorf J, Koller M, Epple M. Toxicity of silver nanoparticles increases during storage because of slow dissolution under release of silver ions. *Chemistry of Materials*. 2010;22(16):4548-54. doi: 10.1021/cm100023p.
118. Scanlan LD, Reed RB, Loguinov AV, Antczak P, Tagmount A, Aloni S, et al. Silver nanowire exposure results in internalization and toxicity to *Daphnia magna*. *Acs Nano*. 2013;7(12):10681-94. doi: 10.1021/nn4034103.
119. Ashraf S, Abbasi AZ, Pfeiffer C, Hussain SZ, Khalid ZM, Gil PR, et al. Protein-mediated synthesis, pH-induced reversible agglomeration, toxicity and cellular interaction of silver nanoparticles. *Colloids and Surfaces B: Biointerfaces*. 2013;102:511-8. doi: 10.1016/j.colsurfb.2012.09.032.
120. El Badawy AM, Silva RG, Morris B, Scheckel KG, Suidan MT, Tolaymat TM. Surface charge-dependent toxicity of silver nanoparticles. *Environmental science & technology*. 2010;45(1):283-7. doi: 10.1021/es1034188.
121. Park E-J, Yi J, Kim Y, Choi K, Park K. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. *Toxicology in Vitro*. 2010;24(3):872-8. doi: 10.1016/j.tiv.2009.12.001
122. Park MV, Neigh AM, Vermeulen JP, de la Fonteyne LJ, Verharen HW, Briedé JJ, et al. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. *Biomaterials*. 2011;32(36):9810-7. doi: 10.1016/j.biomaterials.2011.08.085.
123. Kermanizadeh A, Gaiser BK, Hutchison GR, Stone V. An in vitro liver model-assessing oxidative stress and genotoxicity following exposure of hepatocytes to a panel of engineered nanomaterials. *Particle and fibre toxicology*. 2012;9(1):1. doi: 10.1186/1743-8977-9-28.
124. Piao MJ, Kang KA, Lee IK, Kim HS, Kim S, Choi JY, et al. Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis. *Toxicology letters*. 2011;201(1):92-100. doi: 10.1016/j.toxlet.2010.12.010.
125. Kim YS, Kim JS, Cho HS, Rha DS, Kim JM, Park JD, et al. Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley rats. *Inhalation toxicology*. 2008;20(6):575-83. doi: 10.1080/08958370701874663.
126. Ji JH, Jung JH, Kim SS, Yoon J-U, Park JD, Choi BS, et al. Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats. *Inhalation toxicology*. 2007;19(10):857-71. doi: : 10.1080/08958370701432108.
127. Kiss JE, Brambilla D, Glynn SA, Mast AE, Spencer BR, Stone M, et al. Oral iron supplementation after blood donation: a randomized clinical trial. *JAMA*. 2015;313(6):575-83. doi: 10.1001/jama.2015.119.
128. Fishbane SN, Singh AK, Cournoyer SH, Jindal KK, Fanti P, Guss CD, et al. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. *Nephrology Dialysis Transplantation*. 2015;30(12):2019-26.
129. Choi JS, Koh I-U, Lee HJ, Kim WH, Song J. Effects of excess dietary iron and fat on glucose and lipid metabolism. *The Journal of nutritional biochemistry*. 2013;24(9):1634-44. doi: 10.1016/j.jnutbio.2013.02.004.
130. Costas M, Mehn MP, Jensen MP, Que L. Dioxygen activation at mononuclear nonheme iron active sites: enzymes, models, and intermediates. *Chemical reviews*. 2004;104(2):939-86. doi: 10.1021/cr020628n.
131. Lanz ND, Booker SJ. Auxiliary iron-sulfur cofactors in radical SAM enzymes. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*. 2015;1853(6):1316-34. doi: 10.1016/j.bbamcr.2015.01.002.
132. Soyano A, Gomez M. [Role of iron in immunity and its relation with infections]. *Archivos latinoamericanos de nutricion*. 1999;49(3 Suppl 2):40S-6S.
133. Wen S, Liu D-F, Liu Z, Harris S, Yao Y-Y, Ding Q, et al. OxLDL-targeted iron oxide nanoparticles for *in vivo* MRI detection of perivascular carotid collar induced atherosclerotic lesions in ApoE-deficient mice. *Journal of lipid research*. 2012;53(5):829-38. doi: 10.1194/jlr.M018895.
134. He Y, Song W, Lei J, Li Z, Cao J, Huang S, et al. Anti-CXCR4 monoclonal antibody conjugated to ultrasmall superparamagnetic iron oxide nanoparticles in an application of MR molecular imaging of pancreatic cancer cell lines. *Acta radiologica*. 2012;53(9):1049-58. doi: 10.1258/ar.2012.120055.
135. Daldrup-Link HE, Golovko D, Ruffell B, DeNardo DG, Castaneda R, Ansari C, et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. *Clinical Cancer Research*. 2011;17(17):5695-704. doi: 10.1158/1078-0432.CCR-10-3420.

136. Ittrich H, Peldschus K, Raabe N, Kaul M, Adam G. Superparamagnetic iron oxide nanoparticles in biomedicine: applications and developments in diagnostics and therapy. *Rofo*. 2013;185(12):1149-66. doi: 10.1055/s-0033-1335438.
137. Iv M, Telischak N, Feng D, Holdsworth SJ, Yeom KW, Daldrup-Link HE. Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors. *Nanomedicine*. 2015;10(6):993-1018. doi: 10.2217/nmm.14.203.
138. Mulens V, Morales MdP, Barber DF. Development of magnetic nanoparticles for cancer gene therapy: a comprehensive review. *ISRN Nanomaterials*. 2013;2013.
139. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. *Journal of controlled release*. 2011;155(3):393-9. doi: 10.1016/j.jconrel.2011.06.033.
140. Huang C, Tang Z, Zhou Y, Zhou X, Jin Y, Li D, et al. Magnetic micelles as a potential platform for dual targeted drug delivery in cancer therapy. *International journal of pharmaceutics*. 2012;429(1):113-22. doi: 10.1016/j.ijpharm.2012.03.001
141. Wang M, Thanou M. Targeting nanoparticles to cancer. *Pharmacological Research*. 2010;62(2):90-9. doi: 10.1016/j.phrs.2010.03.005.
142. Glover AL, Bennett JB, Pritchett JS, Nikles SM, Nikles DE, Nikles JA, et al. Magnetic heating of iron oxide nanoparticles and magnetic micelles for cancer therapy. *Magnetics, IEEE Transactions on*. 2013;49(1):231-5.
143. Meenach SA, Shapiro JM, Hilt JZ, Anderson KW. Characterization of PEG-iron oxide hydrogel nanocomposites for dual hyperthermia and paclitaxel delivery. *Journal of Biomaterials Science, Polymer Edition*. 2013;24(9):1112-26. doi: 10.1080/09205063.2012.741321.
144. Laurent S, Dutz S, Häfeli UO, Mahmoudi M. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. *Advances in colloid and interface science*. 2011;166(1):8-23. doi: 10.1016/j.cis.2011.04.003.
145. Zuzana M, Alessandra R, Lise F, Maria D. Safety assessment of nanoparticles cytotoxicity and genotoxicity of metal nanoparticles in vitro. *Journal of biomedical nanotechnology*. 2011;7(1):20-1.
146. Singh SP, Rahman M, Murty U, Mahboob M, Grover P. Comparative study of genotoxicity and tissue distribution of nano and micron sized iron oxide in rats after acute oral treatment. *Toxicology and applied pharmacology*. 2013;266(1):56-66. doi: 10.1016/j.taap.2012.10.016.
147. Soenen SJ, Parak WJ, Rejman J, Manshian B. (Intra) cellular stability of inorganic nanoparticles: effects on cytotoxicity, particle functionality, and biomedical applications. *Chemical Reviews*. 2015;115(5):2109-35. doi: 10.1021/cr400714j.
148. Ahamed M, Alhadlaq H, Alam J, Khan M, Ali D, Alarafi S. Iron oxide nanoparticle-induced oxidative stress and genotoxicity in human skin epithelial and lung epithelial cell lines. *Current pharmaceutical design*. 2013;19(37):6681-90.
149. Bhattacharya K, Hoffmann E, Schins RF, Boertz J, Prantl E-M, Alink GM, et al. Comparison of micro- and nanoscale Fe³⁺-containing (Hematite) particles for their toxicological properties in human lung cells In Vitro. *Toxicological sciences*. 2012;126(1):173-82. doi: 10.1093/toxsci/kfs014.
150. Kucheryavy P, He J, John VT, Maharjan P, Spinu L, Goloverda GZ, et al. Superparamagnetic iron oxide nanoparticles with variable size and an iron oxidation state as prospective imaging agents. *Langmuir*. 2013;29(2):710-6. doi: 10.1021/la3037007.
151. Li Y, Qi L, Shen Y, Ma H. Facile preparation of surface-exchangeable core@ shell iron oxide@ gold nanoparticles for magnetic solid-phase extraction: Use of gold shell as the intermediate platform for versatile adsorbents with varying self-assembled monolayers. *Analytica chimica acta*. 2014;811:36-42. doi: 10.1016/j.aca.2013.12.020.
152. Hong SC, Lee JH, Lee J, Kim HY, Park JY, Cho J, et al. Subtle cytotoxicity and genotoxicity differences in superparamagnetic iron oxide nanoparticles coated with various functional groups. *International journal of nanomedicine*. 2011;6:3219. doi: 10.2147/IJN.S26355.
153. De la Fuente JM, Alcantara D, Penades S. Cell response to magnetic glyconanoparticles: does the carbohydrate matter? *NanoBioscience, IEEE Transactions on*. 2007;6(4):275-81.
154. Soenen SJ, Brisson AR, De Cuyper M. Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. *Biomaterials*. 2009;30(22):3691-701. doi: 10.1016/j.biomaterials.2009.03.040.
155. Soenen SJ, De Cuyper M. Assessing iron oxide nanoparticle toxicity in vitro: current status and future prospects. *Nanomedicine*. 2010;5(8):1261-75. doi: 10.2217/nmm.10.106.
156. Soenen SJ, Rivera-Gil P, Montenegro J-M, Parak WJ, De Smedt SC, Braeckmans K. Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation. *Nano Today*. 2011;6(5):446-65.
157. Pisanic TR, Blackwell JD, Shubayev VI, Fiñones RR, Jin S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. *Biomaterials*. 2007;28(16):2572-81.

158. Könczöl M, Ebeling S, Goldenberg E, Treude F, Gminski R, Gieré R, et al. Cytotoxicity and genotoxicity of size-fractionated iron oxide (magnetite) in A549 human lung epithelial cells: Role of ROS, JNK, and NF- κ B. *Chemical Research in Toxicology*. 2011;24(9):1460-75. doi: 10.1021/tx200051s.
159. Pfaller T, Colognato R, Nelissen I, Favilli F, Casals E, Ooms D, et al. The suitability of different cellular in vitro immunotoxicity and genotoxicity methods for the analysis of nanoparticle-induced events. *Nanotoxicology*. 2010;4(1):52-72. doi: 10.3109/17435390903374001.
160. Zhang T, Qian L, Tang M, Xue Y, Kong L, Zhang S, et al. Evaluation on cytotoxicity and genotoxicity of the L-glutamic acid coated iron oxide nanoparticles. *Journal of nanoscience and nanotechnology*. 2012;12(3):2866-73.
161. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. *New England Journal of Medicine*. 2000;343(5):327-31.
162. Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. *The Cochrane database of systematic reviews*. 2013;8:Cd004450. doi: 10.1002/14651858.CD004450.pub3
163. Kostura L, Kraitichman DL, Mackay AM, Pittenger MF, Bulte JW. Feridex labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. *NMR in Biomedicine*. 2004;17(7):513-7.
164. Chen Y-C, Hsiao J-K, Liu H-M, Lai I-Y, Yao M, Hsu S-C, et al. The inhibitory effect of superparamagnetic iron oxide nanoparticle (Ferucarbotran) on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells. *Toxicology and applied pharmacology*. 2010;245(2):272-9. doi: 10.1016/j.taap.2010.03.011.
165. Wu X, Tan Y, Mao H, Zhang M. Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells. *Int J Nanomedicine*. 2010;5:385-99.
166. Eamegdool SS, Weible MW, Pham BT, Hawsett BS, Grieve SM, Chan-ling T. Ultrasmall superparamagnetic iron oxide nanoparticle prelabelling of human neural precursor cells. *Biomaterials*. 2014;35(21):5549-64. doi: 10.1016/j.biomaterials.2014.03.061.
167. Multhoff G, Hightower LE. Cell surface expression of heat shock proteins and the immune response. *Cell stress & chaperones*. 1996;1(3):167.
168. Zunino B, Rubio-Patino C, Villa E, Meynet O, Proics E, Cornille A, et al. Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90. *Oncogene*. 2015. doi: 10.1038/onc.2015.82.